Friday 25 May |
Hochschild Mining |
Ferrexpo |
Keywords Studios |
Lookers |
Informa |
Spectris |
ContourGlobal |
Old Mutual (re managed separation) |
Monday 28 May |
no events scheduled |
Tuesday 29 May |
Afarak group |
Belvoir Lettings |
Eddie Stobart Group |
Standard Life Aberdeen |
Oxford Biomedica |
Harworth Group |
Playtech (re acquisition of Snaitech) |
Wednesday 30 May |
AG Barr |
Bodycote |
Crudader Resources |
Royal Bank of Scotland Group |
Frenkel Topping Group |
Safestyle UK |
Fresnillo |
Thursday 31 May |
Brady |
Card Factory |
e-Therapeutics |
Faron Pharmaceuticals |
Porta Communications |
Total Produce |
Northbridge Industrial |
Sirius Minerals |
Faron reveals details of next stage of bexmarilimab study
(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).
Read more